Archive
Every story, newest first.
Friday, October 30, 2026
Life Sciences
Merck reported third quarter sales up 5 percent to $18.1 billion on October 29, with combined Keytruda and Keytruda Qlex sales up 6 percent to $8.6 billion, including $830 million from the Qlex injection in its strongest quarter since launch.
Life Sciences
Genmab's market value rose by more than $7 billion to pass $35 billion after its Phase 3 win, and the UK Autumn Budget carried more than £1 billion of life sciences investment pledges, leading the smaller life sciences items for October 30.
Life Sciences
The Department of Labor finalized a rule on October 29 requiring pharmacy benefit managers to disclose their compensation, including rebates and spread pricing, to large self insured employer plans, with requirements applying to plan years starting July 1, 2027.
Life Sciences
Iovance reported on October 29 that lifileucel produced a 24.6 percent response rate in 69 patients with previously treated non squamous lung cancer, rising to 59.1 percent in a retrospectively defined biomarker subgroup of 22 patients, and will test that subgroup prospectively in a new registrational intent study from November.
Life Sciences
Incyte reported third quarter total revenue up 14 percent to $1.56 billion on October 29 and raised full year total net sales guidance to $5.210 billion to $5.300 billion, as Opzelura sales rose 36 percent to $255 million.
Life Sciences
Gilead reported third quarter product sales up 13 percent to $8.3 billion on October 29 and raised full year product sales guidance to $31.0 billion to $31.3 billion, from $30.1 billion to $30.4 billion, as HIV sales rose 18 percent.
Life Sciences
Dren Bio announced on October 29 the closing of an oversubscribed $350 million private financing, co led by Juvia Group and Lightspeed Venture Partners, to fund late stage development, regulatory submission and a planned commercial launch of its CD94 antibody dibotatug.
Life Sciences
Bristol Myers Squibb reported third quarter revenues up 7 percent to $13.1 billion on October 29 and raised full year 2026 revenue guidance to $49.75 billion to $50.25 billion, as growth portfolio revenues rose 12 percent to $7.7 billion.
Politics
Azerbaijan's President Ilham Aliyev will not attend Friday's Organization of Turkic States summit in Ankara, sending his foreign minister instead, in an absence widely read as a signal of strain with Turkiye over its criticism of Azerbaijan's school headscarf restrictions.
Politics
Opposition lawmakers set off flares and smoke bombs in Albania's parliament on Thursday and blocked a central bank bill vote, after weeks of student led protests demanding Prime Minister Edi Rama's resignation.